Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration
Preprint
- 28 March 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
The pathophysiological mechanisms driving disease progression of frontotemporal lobar degeneration (FTLD) and corresponding biomarkers are not fully understood. We leveraged aptamer-based proteomics (> 4,000 proteins) to identify dysregulated communities of co-expressed cerebrospinal fluid proteins in 116 adults carrying autosomal dominant FTLD mutations (C9orf72, GRN, MAPT) compared to 39 noncarrier controls. Network analysis identified 31 protein co-expression modules. Proteomic signatures of genetic FTLD clinical severity included increased abundance of RNA splicing (particularly in C9orf72 and GRN) and extracellular matrix (particularly in MAPT) modules, as well as decreased abundance of synaptic/neuronal and autophagy modules. The generalizability of genetic FTLD proteomic signatures was tested and confirmed in independent cohorts of 1) sporadic progressive supranuclear palsy-Richardson syndrome and 2) frontotemporal dementia spectrum syndromes. Network-based proteomics hold promise for identifying replicable molecular pathways in adults living with FTLD. ‘Hub’ proteins driving co-expression of affected modules warrant further attention as candidate biomarkers and therapeutic targets.Keywords
All Related Versions
- Version 1, 2024-03-28, Research Square
- Published version: Nature Aging, 5 (6), 1143.
This publication has 71 references indexed in Scilit:
- Plasma phosphorylated tau‐217 exhibits sex‐specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adultsAlzheimer's & Dementia, 2023
- Network Connectivity Alterations across the MAPT Mutation Clinical SpectrumAnnals of Neurology, 2023
- [18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementiaAlzheimer's & Dementia, 2022
- Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's diseaseAlzheimer's & Dementia, 2021
- The role of hnRNPs in frontotemporal dementia and amyotrophic lateral sclerosisActa Neuropathologica, 2020
- Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDSAlzheimer's & Dementia, 2020
- Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS ConsortiumAlzheimer's & Dementia, 2020
- Genetic screening of a large series of North American sporadic and familial frontotemporal dementia casesAlzheimer's & Dementia, 2020
- Neuronatin Protein in Health and DiseaseJournal of Cellular Physiology, 2016